Skip to content

Press Release · Press Releases · Asia-Pacific

Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance

Issued by PR Newswire

Differentiated trispecific TIGIT-Fc ligand-trap strategy aims to address CD226 downregulation, a potential limitation of conventional anti-TIGIT antibodies U.S FDA clearance followed by accelerated Taiwan TFDA approval advances HCB303 toward multi-regional Phase 1 clinical development...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories